spacer
home > ebr > spring 2002 > building value through biotechnology partnering
PUBLICATIONS
European Biopharmaceutical Review

Building Value Through Biotechnology Partnering

It is critical for early stage biotechnology companies to build long-term sustainable value. 'Early stage' is intended to include any company - public or private - without recurring revenue from product sales, so the vast majority of biotech companies are included in this definition. Everyone seeks high value partnerships with major pharmaceutical companies, but either companies partner early, giving away a very significant portion of their long-term value, or they fail to build the full range of capabilities in a timely manner to enable the underlying value of their technology to be realised. In addition, pharma-biotech collaborations are challenging to manage, not least because of the significant cultural differences between the two types of organisation. Collaborations between biotechs offer a means of rapidly building value, but often these biotech-biotech deals fail to deliver. In this article, pharma-biotech and biotech-biotech collaborations are analysed, common reasons for failure are identified, and some models for successful biotech-biotech collaborations are discussed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Mike Grey, Chief Business Officer at Structural GenomiX, Inc.

Mike Grey is Executive Vice President, Chief Business Officer and a Director of Structural GenomiX, Inc. - a San Diego-based drug discovery company utilising a genomics-driven, high throughput platform that enables the determination of the 3-D structures of large numbers of proteins and protein/compound co-crystals very rapidly.
A chemist by training, Mike has held senior positions in a number of North American Biotechnology companies, including President and Chief Executive Officer of Trega Biosciences, Inc. and President of BioChem Therapeutic, Inc., the pharmaceutical operating division of BioChem Pharma Inc. From 1974 to 1993, he served in various roles with Glaxo Inc. and Glaxo Holdings, p.l.c., culminating in his position as Vice President, Corporate Development and Director, International Licensing. Mike also serves on the board of several US biotechnology companies.

spacer
Mike Grey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo includes Sheremetyevo Airport near Moscow to its cargo flights network.

As the fastest growing brand among the global air cargo carriers with its extensive flights network, Turkish Cargo included Sheremetyevo Airport (SVO), known as being the most important airport in Russia in terms of cargo activities, to its direct cargo flight destinations network.
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement